Tuesday, July 21, 2026 at 2pm ET                        Pricing: Free for Members and Non-Members

Please note that this session is not accredited for continuing pharmacy education credit.

Program Description

Traditional antidepressants fail millions of patients with treatment-resistant depression (TRD), driving up healthcare costs and leaving individuals without relief. As psilocybin and other psychedelic-assisted therapies approach regulatory reality, managed care leaders face an unprecedented operational and clinical shift in managing these patients.

Join us as AMCP Market Insights shares exclusive findings from our recent multi-stakeholder expert roundtable. This webinar will break down payer perspectives on clinical data, address the looming provider network shortage, and outline actionable strategies to prepare your behavioral health network for these emerging interventional treatments. Attendees will walk away with concrete recommendations on removing care barriers, updating coverage frameworks, and driving cross-industry collaboration to evaluate, cover, and operationalize these therapies safely and effectively.

Ultimately, preparing for this shift is about more than logistics. It is about evaluating how best to integrate clinical advancements that hold the potential to completely rewrite the patient experience, offering rapid, sustained remission and restoring quality of life to individuals who have lived for years without hope.